Therapeutic Area

Endocrinology

Therapeutic area intelligence for Endocrinology with 16 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 16
Catalysts: 0
Companies: 4

Companies

Assets

Recent signals(16)

ClinicalJune 21, 2026

Study on Exercise Programs for Women with PCOS Initiated by Biruni University

A clinical trial is underway to assess the effectiveness of a digital rehabilitation-supported exercise program in women with PCOS.

ClinicalJune 21, 2026

Study on Sleep Regularity's Impact on Glycemic Control in Type 1 Diabetes

A mechanistic study will explore how improving sleep regularity affects glycemic control and cardiovascular risk in individuals with type 1 diabetes.

ClinicalJune 21, 2026

Dulce Digital 2.0 Study Aims to Enhance Diabetes Self-Management via Digital Tools

The Dulce Digital 2.0 study will evaluate two mHealth adaptations aimed at improving digital health literacy and self-management in underserved diabetes populations.

RegulatoryJune 21, 2026

FDA Approves Supplement for Estradiol by Mylan Technologies

The FDA has approved a supplemental application for estradiol submitted by Mylan Technologies.

ClinicalJune 21, 2026

Clinical Trial on Anti-inflammatory Diet's Impact on Type 2 Diabetes Management

A randomized controlled trial is evaluating the effects of an anti-inflammatory dietary intervention on inflammation and glycemic control in patients with type 2 diabetes.

ClinicalJune 20, 2026

Genetic Variants ERBB4 and SHBG Linked to PCOS Risk in South Indian Women

The study investigates the association of ERBB4 and SHBG gene polymorphisms with the risk of polycystic ovary syndrome in South Indian women.

ClinicalJune 20, 2026

Eli Lilly's Orforglipron Study in Adolescents with Obesity Underway

Eli Lilly is conducting a study to evaluate the efficacy and safety of orforglipron in adolescents with obesity or related comorbidities.

ClinicalJune 19, 2026

Edinburgh Study Investigates Pancreas Lipotoxicity and Weight Loss in Type 2 Diabetes

The Edinburgh Diabetes Remission Study aims to explore the role of fat accumulation in the pancreas and its impact on type 2 diabetes remission through weight loss.

RegulatoryJune 18, 2026

FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca

The FDA has accepted the New Drug Application for BAXFENDY (BAXDROSTAT) from AstraZeneca.

RegulatoryJune 17, 2026

FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List

The FDA has proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, indicating no clinical need for compounding these drugs.

RegulatoryJune 16, 2026

FDA Approves Tzield for Pediatric Patients with Stage 3 Type 1 Diabetes

The FDA granted accelerated approval for Tzield (teplizumab) to delay insulin production decline in pediatric patients with Stage 3 T1D.

ClinicalJune 16, 2026

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

StrategyJune 16, 2026

Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women

In clinical trials, Foundayo demonstrated significant weight loss in women across all stages of menopause, with losses up to 30.4 lbs.

CompetitiveJune 16, 2026

Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes

Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.

ClinicalJune 13, 2026

Phase II Trial of SAL0140 Shows Promise for Primary Aldosteronism

A Phase II clinical trial is underway to evaluate the efficacy and safety of SAL0140 at varying doses in patients with primary aldosteronism.

ClinicalJune 10, 2026

AI-Driven Nutrition Study for Type 2 Diabetes Shows Promise for Glycemic Control

The AIM-MET study is evaluating a microbiome-targeted nutritional product's effect on glycemic control in type 2 diabetes over 24 weeks.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Obesity →

Polycystic Ovary Syndrome →

Type 1 Diabetes →

Type 2 Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.